OR WAIT null SECS
Sunderland-based science company Complement Genomics Ltd (CGL) has entered into a partnership with a leading US provider of genomic services for clinical trials and research, in order to conduct studies to improve the lives of those suffering from a variety of debilitating illnesses.
By partnering with Expression Analysis Inc., CGL will gain access to technology unprecedented elsewhere in the UK, allowing them to screen large numbers of patients with specific conditions, identifying genes associated with neurodegenerative disease and other conditions including cancer, diabetes and Parkinson’s.
Louise Allcroft, Chief Executive Officer of CGL, says: “The high-volume, whole genome approach we can now adopt has been fundamental in improving scientists’ understanding of complex disorders. It will allow us to gain further insight into the involvement of genes in the manifestation of many diseases, and contribute not only to the development of new diagnostic tests but also aid the development and design of new modes of treatment.”
Expression Analysis Inc. is a leading international provider of genomic services in clinical trials and research, offering experimental design consultation, biologic sample preparation, sample processing and data analysis services to clients worldwide.
Steve McPhail, President and CEO of Expression Analysis, says: “The partnership with CGL and their Geneblitz service provides us with an established presence in the United Kingdom, with an experienced service provider who operates with the same philosophy and similar quality standards and platforms.”
CGL operates a successful paternity testing division under the brand name, dadcheck, as well as providing a comprehensive range of services to the biotechnology sector such as genotyping, DNA sequencing, forensic testing and a number of toxicology and drug analysis protocols in addition to its own research programs in wound care.